CA2202533A1 - Recepteur humain her4 a activite tyrosine-kinase - Google Patents
Recepteur humain her4 a activite tyrosine-kinaseInfo
- Publication number
- CA2202533A1 CA2202533A1 CA002202533A CA2202533A CA2202533A1 CA 2202533 A1 CA2202533 A1 CA 2202533A1 CA 002202533 A CA002202533 A CA 002202533A CA 2202533 A CA2202533 A CA 2202533A CA 2202533 A1 CA2202533 A1 CA 2202533A1
- Authority
- CA
- Canada
- Prior art keywords
- her4
- leu
- gly
- pro
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF] (urogastrone)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention se rapporte au clonage moléculaire, à l'expression et aux caractéristiques biologiques d'un nouveau récepteur à activité tyrosine-kinase, apparenté au récepteur du facteur de croissance de l'épiderme, et appelé HER4/p180?erbB4¿. Un ligand de HER4 pouvant induire la différenciation cellulaire des cellules du cancer du sein est également décrit. L'HER4 étant exprimé dans plusieurs cancers humains et dans certains tissus d'origine neuronale et musculaire, différentes utilisations d'ordre thérapeutique et diagnostique de compositions biologiques apparentées à l'HER4 et dérivées d'HER4 sont décrites.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32344294A | 1994-10-14 | 1994-10-14 | |
US08/323,442 | 1994-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2202533A1 true CA2202533A1 (fr) | 1996-04-25 |
Family
ID=23259216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002202533A Abandoned CA2202533A1 (fr) | 1994-10-14 | 1995-10-10 | Recepteur humain her4 a activite tyrosine-kinase |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0787187A1 (fr) |
JP (1) | JPH10507362A (fr) |
AU (1) | AU3963295A (fr) |
CA (1) | CA2202533A1 (fr) |
FI (1) | FI971532A (fr) |
IL (1) | IL115642A0 (fr) |
MX (1) | MX9702664A (fr) |
NO (1) | NO971686L (fr) |
WO (1) | WO1996012019A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU9805398A (en) * | 1997-10-15 | 1999-05-03 | Children's Medical Center Corporation | Novel human egf receptors and use thereof |
WO1999023209A2 (fr) * | 1997-10-31 | 1999-05-14 | Georgetown University Medical Center | RIBOZYMES CIBLEES SUR ErbB-4 |
CA2515081A1 (fr) | 2003-02-07 | 2004-08-19 | Protein Design Labs, Inc. | Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis |
US8652787B2 (en) | 2008-11-12 | 2014-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of ERBB4 as a prognostic and therapeutic marker for melanoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2103323A1 (fr) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Tyrosine kinase du recepteur her4 humain |
-
1995
- 1995-10-10 CA CA002202533A patent/CA2202533A1/fr not_active Abandoned
- 1995-10-10 AU AU39632/95A patent/AU3963295A/en not_active Abandoned
- 1995-10-10 MX MX9702664A patent/MX9702664A/es unknown
- 1995-10-10 WO PCT/US1995/013524 patent/WO1996012019A2/fr not_active Application Discontinuation
- 1995-10-10 EP EP95937555A patent/EP0787187A1/fr not_active Withdrawn
- 1995-10-10 JP JP8513469A patent/JPH10507362A/ja active Pending
- 1995-10-15 IL IL11564295A patent/IL115642A0/xx unknown
-
1997
- 1997-04-11 FI FI971532A patent/FI971532A/fi not_active IP Right Cessation
- 1997-04-11 NO NO971686A patent/NO971686L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU3963295A (en) | 1996-05-06 |
JPH10507362A (ja) | 1998-07-21 |
NO971686L (no) | 1997-06-16 |
WO1996012019A2 (fr) | 1996-04-25 |
FI971532A0 (fi) | 1997-04-11 |
WO1996012019A3 (fr) | 1996-08-15 |
FI971532A (fi) | 1997-06-11 |
MX9702664A (es) | 1997-06-28 |
EP0787187A1 (fr) | 1997-08-06 |
IL115642A0 (en) | 1996-01-19 |
NO971686D0 (no) | 1997-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5811098A (en) | Antibodies to HER4, human receptor tyrosine kinase | |
EP0599274A1 (fr) | HER4, récepteur tyrosine kinase de la famille du récepteur de facteur de croissance épidermique | |
EP0912734B1 (fr) | Adhesines heteromultimeres chimeriques | |
US8226935B2 (en) | ErbB2 and ErbB3 chimeric heteromultimer receptors | |
US5916755A (en) | Methods of characterizing ligands for the erbB-3 receptor, methods of influencing erbB-3 activities and methods of diagnosing erbB-3-related neoplasm | |
AU2018202982A1 (en) | Fusion immunomodulatory proteins and methods for making same | |
Jeschke et al. | Targeted inhibition of tumor‐cell growth by recombinant heregulin‐toxin fusion proteins | |
AU4228693A (en) | Recombinant stimulating factor of the (NEU) receptor | |
US20020002276A1 (en) | Chimeric heteromultimer adhesins | |
EP0828843A1 (fr) | Heregulines de recombinaison et leurs fonctions biologiques lors de l'activation d'un recepteur | |
CA2202533A1 (fr) | Recepteur humain her4 a activite tyrosine-kinase | |
WO1996012019A9 (fr) | Recepteur humain her4 de type tyrosine-kinase appartenant a la famille des facteurs de croissance de l'epiderme | |
QIAN et al. | Identification of pl85neu sequences required for monoclonal antibody-or ligand-mediated receptor signal attenuation | |
MXPA99000376A (en) | Adhesives heteromultimeras quimeri |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |